The Latest Breaking News from Gilead Sciences

Earnings Preview: What to Expect From Gilead Sciences’ Report

Gilead Sciences is set to report its Q3 results soon, with analysts projecting a double-digit year-over-year decline in EPS.

Barchart · Oct 13

Dr Reddy's inks pact with Gilead for once-yearly HIV prevention drug lenacapavir

Dr Reddy's Laboratories and Gilead Sciences have signed a licensing agreement. This pact involves investigational once-yearly lenacapavir for HIV prevention. The agreement facilitates manufacturing and supply planning for 120 countries. This collaboration builds upon a previous pact for twice-yearly lenacapavir.

The Economic Times · Sep 17

Early Remdesivir Tracked with About 25 Percent Lower Death Risk in Hospitalized Patients with Kidney Disease

A claims-based study of 27,000 hospitalized COVID patients links early remdesivir to lower 28-day death risk. Gilead helped conduct the research.

Medical Daily · Sep 3

Hepatitis Delta Is the Deadliest Form of Viral Hepatitis — and the U.S. Just Got Its First Treatment for It

FDA granted accelerated approval to Hepcludex (bulevirtide) for Hepatitis Delta on May 22, 2026 — the first-ever U.S. treatment for HDV. What patients need to know.

Medical Daily · Jun 16

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w

MarketBeat · Jun 5

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

MarketBeat · May 24

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca

MarketBeat · May 17

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart · Apr 30

Why this Gilead Sciences exec says managing energy, not time, drives performance

At Gilead Sciences, its chief commercial officer says managing energy matters more than managing time.

Fortune · Apr 13

2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

Barchart · Mar 16